Nanotechnology applications are being applied across a diverse spectrum of industries. The last few years have witnessed the maturation of several nanotechnologies that, along with recent breakthroughs, can open new market opportunities. Furthermore, several unique ideas have been developed in individual researchers' laboratories and these await translation to the technology arena. These nanomaterials and nanotechnologies present great promise in addressing global issues related to energy, environment, and human health and provide outstanding opportunities for investment. This one-day Workshop will provide a forum for individuals to present proven research ideas that are either patented or are in the final stages of development with the objective to link them to potential investors and/or technology partners.
The Workshop will be brought to the attention of individual investors, organizations, corporations, and various departments and chambers of commerce world-wide (US, EU, etc.). Individuals are welcome to participate and present their intellectual property and explore its future commercialization with Workshop participants. The overall objective is to facilitate the transfer of developed nanotechnologies to the market place.
Submit a short Abstract with a title of the technology, name(s) and affiliation of inventor(s)/researcher(s) to email@example.com. Depending on the number of responses, your research can be presented either as a 15 min oral presentation or as a poster presentation.
Bio: John Randall, President of Zyvex Labs and Adjunct Professor at UT Dallas, has over 30 years of experience in Micro- and Nano- Fabrication. He joined Zyvex in March of 2001 after 15 years at Texas Instruments where he worked in high resolution processing for integrated circuits, MEMS, and quantum effect devices. Prior to working at TI, John worked at MIT's Lincoln Laboratory on ion beam and x-ray lithography. He has 96 articles published in refereed journals with over 2000 citations and 25 issued US Patents with over 600 citations.
Bio: Penelope Salmons leverages over twenty years of global management experience in facilitating businesses to transform by monetizing their hard and soft assets. Her experience spans the sectors of Nanotechnology, Capital Markets, High-Tech, Healthcare, Life Sciences and Energy. She has held executive and equity positions in Rosseter NanoComposites, LLC and Rosseter Holdings, Ltd. Prior to that she was a Managing Director in a Strategic Banking NY VC, a Sr. Director at InforMax (Bioinformatics) and principal with IBM. Penelope holds a Master degree from Harvard University in 07 and her Bachelor in Computer Sciences from the University of Florida in 1980.
NanoBusiness Commercialization Association
Successful Nanotechnology Commercialization: Case Study
Andreas Mershin, MIT
Lab to market the MIT Way
Abstract: Sharp focus on curiosity-driven basic research, coupled with an "impact over income" culture allow MIT to excel in both academic discovery and global entrepreneurial output. Companies founded by MIT alums have annual global sales amounting to $2 trillion -if taken as a nation this would rank as the 11th largest economy. This talk will discuss key aspects behind the success of the "MIT way" that fly in the face of traditional lab-to-market methodologies. These include a unique treatment of intellectual property, academic publications, student involvement, early prototyping, risk management and industrial and government sponsor relations.
Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg
Translational Think Tank, MIT - Massachusetts Institute of Technology, Department of Brain & Cognitive Sciences (Germany/USA)
Nanotechnology Ventures Based on Research
Dimitrios Ioannidis, Esq
Roach, Ioannidis & Megaloudis, LLC
The art of raising capital: getting an idea to the marketplace and succeeding
Abstract: The presentation will center on how Boston has become the second largest center for venture capital firms and hedge funds. How the State of Massachusetts has implemented a “Mass Life Sciences fund” during the past years and how it developed a “cluster” of Biotech firms. How it coordinated the financing of universities and private firms by building a quality support network of resources to foster the growth in the sector. The roadmap for raising capital in a global environment. How to approach the commercialization of ideas, from securing and protecting ideas, to negotiating agreements with VCs and other funding partners. Developing a plan that works for the scientist with innovative ideas in a commercialized world that can only capitalize a few opportunities.